These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1411865)

  • 41. Whole blood superoxide anion generation and efficiency of some erythrocyte antioxidant systems during recombinant human erythropoietin therapy of uremic anemia.
    Luciak M; Pawlicki L; Kedziora J; Trznadel K; Błaszczyk J; Buczyński A
    Free Radic Biol Med; 1991; 10(6):397-401. PubMed ID: 1654288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    J Am Soc Nephrol; 1994 Apr; 4(10):1809-13. PubMed ID: 8068879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute carbon monoxide poisoning alters hemorheological parameters in human.
    Ozturk B; Arihan O; Coskun F; Dikmenoglu-Falkmarken NH
    Clin Hemorheol Microcirc; 2016; 61(4):591-7. PubMed ID: 25536918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rheological properties of red blood cells (including reticulocytes) in patients with chronic renal disease.
    Nowak E; Wyrwicz G; Dabrowski Z; Smoleńiski O; Spodaryk K
    Clin Hemorheol Microcirc; 1999; 21(2):87-94. PubMed ID: 10599591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 47. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 49. The effect of recombinant human erythropoietin (r-Hu EPO) administration on the blood chemistries and composition in uremic rats.
    Kozioł M; Ksiazek P; Feldo M; Spasiewicz D; Michalak J; Kleinrok Z
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():61-6. PubMed ID: 8192533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits.
    Paulitschke M; Ludat K; Riedel E; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S36-41. PubMed ID: 10746804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in endocrinological functions in hemodialysis patients associated with improvements in anemia after recombinant human erythropoietin therapy.
    Akizawa T; Kinugasa E; Nakayama F; Takahashi T; Koshikawa S; Shimizu N
    Contrib Nephrol; 1990; 82():86-93. PubMed ID: 2093532
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of propofol compared to high-dose fentanyl anesthesia on rheologic parameters in coronary artery surgery.
    Mokken FC; Henny CP; Gelb AW; Biervliet JD; Hardeman MR; Kedaria M; van Wezel HB
    J Cardiothorac Vasc Anesth; 1993 Feb; 7(1):10-6. PubMed ID: 8431560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant human erythropoietin and high flux haemodiafiltration.
    Lippi A; Rindi P; Baronti R; Caprioli R; Favilla G; Palmarini D; Cioni L
    Nephrol Dial Transplant; 1995; 10 Suppl 6():51-4. PubMed ID: 8524496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients.
    Vaziri ND; Ritchie C; Brown P; Kaupke J; Atkins K; Barker S; Hyatt J
    ASAIO Trans; 1989; 35(3):505-8. PubMed ID: 2597519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Erythropoietin--the first hematologic hormone in clinical use].
    Rhyner K
    Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability.
    Johnson WJ; McCarthy JT; Yanagihara T; Osmundson PJ; Ilstrup DM; Jenson BM; Bowie EJ
    Kidney Int; 1990 Nov; 38(5):919-24. PubMed ID: 2266676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cerebrovascular incidents in 4 hemodialysis patients treated with erythropoietin].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1988 Oct; 118(40):1423-6. PubMed ID: 3187475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
    Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
    Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.